相关实验视频

Updated: Jun 15, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

CDK4/6抑制剂加上内分泌疗法对抗HR+/HER2-晚期乳腺癌的安慰剂加上内分泌疗法:基于III期RCT的元分析

Cailu Luo¹, Kunlin Yu¹, Xiaodan Luo¹

¹Department of General Surgery, Yichun People's Hospital, No. 1061 Jinxiu Avenue, Yiyang New District, Yichun, jiangxi, 336000, China.

|August 21, 2024

概括

在内分泌疗法 (ET) 中添加循环素依赖性激酶4/6 (CDK4/6) 抑制剂显著改善了晚期激素受体阳性 (HR+) /HER2-乳腺癌的生存结果. 虽然有效,但这种组合疗法 (CET) 增加了不良事件,特别是血液病性事件.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

激素受体阳性 (HR+),人体表皮生长因子受体2-阴性 (HER2-) 晚期乳腺癌仍然是一个重大的临床挑战.
结合循环素依赖性激酶4/6 (CDK4/6) 抑制剂与内分泌疗法 (ET) 改善生存结果的疗效正在研究中.

研究的目的:

为了比较CDK4/6抑制剂+ET (CET) 与安慰剂+ET (PET) 在HR+/HER2-晚期乳腺癌中的抗瘤疗效和安全性.
评估CET对整体生存 (OS) 和无进展生存 (PFS) 的影响.

主要方法:

进行了第三期随机对照试验 (RCT) 的元分析.
通过全面的数据库搜索,确定了七个符合条件的RCT,将CET与PET进行比较.
主要终点包括OS和PFS;次要终点是反应率和不良事件 (AE).

主要成果:

与PET相比,CET显著改善了OS (HR:0.81) 和PFS (HR:0.57).与PET相比,CET显著改善了OS (HR:0.81) 和PFS (HR:0.57).
客观反应率 (RR: 1.31) 和临床益处率 (RR: 1.11) 也显著高于CET.
虽然CET在各个子组中显示出更高的生存益处,但它与总体,3-5级和严重的副作用,特别是中性病和白血病的发病率更高有关.

结论:

与ET (CET) 结合的CDK4/6抑制剂为HR+/HER2-晚期乳腺癌患者提供了显著的生存优势.
随着CET效率的提高,不良事件的风险增加,特别是血液毒性,需要仔细监测和管理.

关键词:

乳腺癌乳腺癌乳腺癌这是一种CDK4/6抑制剂.内分泌疗法是一种内分泌疗法.进行元分析分析.随机对照试验是随机对照试验.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...